Akari Therapeutics Plc

Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending 2021-12-31

Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending 2017-12-31

Quarterly Report for period ending 2016-03-31

Annual Report for period ending 2015-12-31

Quarterly Report for period ending 2015-09-30

Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB for period ending 2015-09-30

Quarterly Report for period ending 2015-06-30

Quarterly Report for period ending 2015-03-31

Annual Report for period ending 2014-12-31

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Exempt (Private) Offering

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Notice of Effectiveness

Notice of Effectiveness

Post-effective amendment to a registration statement that is not immediately effective upon filing

Post-effective amendment to a registration statement that is not immediately effective upon filing

Registration statement for specified transactions by certain foreign private issuers

RPC Pharma Ltd: Major Shareholders

WILLIAMS DONALD A: Initial statement of beneficial ownership of securities

Jacques Rachelle Suzanne: Initial statement of beneficial ownership of securities

Prudo-Chlebosz Raymond: Initial statement of beneficial ownership of securities

DICICCO WENDY F: Initial statement of beneficial ownership of securities

Hashad Mohamed Wa'el Ahmed: Initial statement of beneficial ownership of securities

Grissinger Michael: Initial statement of beneficial ownership of securities

Patel Samir Rashmikant: Initial statement of beneficial ownership of securities

RPC Pharma Ltd: Major Shareholders

RPC Pharma Ltd: Major Shareholders

Prospectus filed pursuant to Rule 424(b)(3)

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Prospectus filed pursuant to Rule 424(b)(5)

Prospectus filed pursuant to Rule 424(b)(3)

Prospectus filed pursuant to Rule 424(b)(5)

Prospectus filed pursuant to Rule 424(b)(5)

Prospectus filed pursuant to Rule 424(b)(5)

Prospectus filed pursuant to Rule 424(b)(3)

Prospectus filed pursuant to Rule 424(b)(3)

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive proxy statements

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive proxy statement relating to a merger, acquisition, or disposition

Preliminary proxy statement relating to a merger, acquisition, or disposition

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.